DE3853383D1 - Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit. - Google Patents

Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.

Info

Publication number
DE3853383D1
DE3853383D1 DE3853383T DE3853383T DE3853383D1 DE 3853383 D1 DE3853383 D1 DE 3853383D1 DE 3853383 T DE3853383 T DE 3853383T DE 3853383 T DE3853383 T DE 3853383T DE 3853383 D1 DE3853383 D1 DE 3853383D1
Authority
DE
Germany
Prior art keywords
fsh
isolation
chain proteins
suppressing activity
follicular liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3853383T
Other languages
English (en)
Other versions
DE3853383T2 (de
Inventor
Kretser David De
Henry Burger
Milton Hearn
David Milne-Robertson
Richard Wettenhall
Robert Mclachlan
Vos Fiona De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
Biotech Australia Pty Ltd
Monash University
Prince Henrys Institute of Medical Research
Original Assignee
St Vincents Institute of Medical Research
Biotech Australia Pty Ltd
Monash University
Prince Henrys Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Vincents Institute of Medical Research, Biotech Australia Pty Ltd, Monash University, Prince Henrys Institute of Medical Research filed Critical St Vincents Institute of Medical Research
Publication of DE3853383D1 publication Critical patent/DE3853383D1/de
Application granted granted Critical
Publication of DE3853383T2 publication Critical patent/DE3853383T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE3853383T 1987-01-29 1988-01-29 Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit. Expired - Lifetime DE3853383T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPI008187 1987-01-29
AUPI252587 1987-06-17
AUPI576687 1987-12-07
AUPI576587 1987-12-07
PCT/AU1988/000024 WO1988005789A1 (en) 1987-01-29 1988-01-29 Isolation of single chain proteins with fsh suppressing activity from follicular fluid

Publications (2)

Publication Number Publication Date
DE3853383D1 true DE3853383D1 (de) 1995-04-27
DE3853383T2 DE3853383T2 (de) 1995-07-27

Family

ID=27424192

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3853383T Expired - Lifetime DE3853383T2 (de) 1987-01-29 1988-01-29 Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.

Country Status (7)

Country Link
US (1) US5470826A (de)
EP (1) EP0299050B1 (de)
JP (1) JP2802633B2 (de)
AT (1) ATE120209T1 (de)
AU (1) AU610858B2 (de)
DE (1) DE3853383T2 (de)
WO (1) WO1988005789A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368992B1 (de) * 1988-05-31 1995-02-15 Biotechnology Australia Pty. Ltd. Wirkung von hormonen
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US6407205B1 (en) * 1997-06-04 2002-06-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College FSH-releasing peptides
NZ518320A (en) 1999-10-18 2003-10-31 Prince Henrys Inst Med Res Immuno-interactive fragments of the alphaC subunit of inhibin
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US8920806B2 (en) 2003-10-06 2014-12-30 Paranta Biosciences Limited Method of modulating inflammatory response by downregulation of activin
WO2007130673A2 (en) * 2006-05-05 2007-11-15 Beth Israel Deaconess Medical Center Methods for the diagnosis and treatment of female infertility using molecular markers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215130A (en) * 1977-05-31 1980-07-29 Richardson-Merrell Inc. Antihypertensive compositions of N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine and N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-benzenemethanamine
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
US4833128A (en) * 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
US5041538A (en) * 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception

Also Published As

Publication number Publication date
ATE120209T1 (de) 1995-04-15
EP0299050B1 (de) 1995-03-22
WO1988005789A1 (en) 1988-08-11
AU1242188A (en) 1988-08-24
JPH01502662A (ja) 1989-09-14
AU610858B2 (en) 1991-05-30
EP0299050A1 (de) 1989-01-18
JP2802633B2 (ja) 1998-09-24
DE3853383T2 (de) 1995-07-27
US5470826A (en) 1995-11-28
EP0299050A4 (de) 1990-04-10

Similar Documents

Publication Publication Date Title
NL930137I2 (nl) Polypeptiden, werkwijzen voor hun bereiding, farmaceutische preparaten die deze polypeptiden bevatten en hun toepassing.
MX9302917A (es) Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
GR80840B (en) Novel polypeptide with a - amylase inhibiting effect, method for the preparation thereof, use and pharmaceutical preparations thereof
DK322188A (da) Fremgangsmaade til fremstilling af protein
PT94381A (pt) Processo para a preparacao de uma composicao contendo um imunogeno para tratamentos antialergicos
DE2962569D1 (en) Immune serum globulin preparations and method to produce them
NO873699L (no) Polypeptid som er egnet til dempning, behandling og diagnostisering av autoimmune lidelser saasom leddbetennelser.
ATE246248T1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
DE3853383D1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
GB1520162A (en) Bone joint prosthesis
DE3382718D1 (de) Peptide, die eine Immunogen-Lage des Poliovirus des Sabin-Stammes enthalten.
KR910003095A (ko) 사람의 단백질 c변이체 및 이의 제조방법
Costa et al. Correlation of Cenozoic dinoflagellate and nannoplankton zones from the NE Atlantic and NW Europe
DE3880520D1 (de) Rekombinantes plasmid fuer die expression von l-phenylalanin-ammonialyase und transformierte staemme, die es enthalten.
ATE63904T1 (de) Azolderivate, geeignet zur bekaempfung von pflanzen-krankheiten.
SE8700156L (sv) Kosmetiska kompositioner med hudlugnande och hudgenerande effekt och forfarande for framstellning derav
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
ES2063161T3 (es) Proteinas modificadas.
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego
SE7909788L (sv) Sett att framstella en antihemofilifaktor
JPS53142593A (en) Stabilization of urokinase by heating
IT8421612A0 (it) Vettore clonante, procedimento per la sua costruzione e procedimentodi concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition